A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia

LEUKEMIA & LYMPHOMA

TAYLOR & FRANCIS LTD

1. NHLBI NIH HHS [K08 HL111280] Funding Source: Medline